From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Months of treatment
< 4
4
> 4
Total
No. of patients
3
14
15
32
Median duration (range) (in days)
65 (56–94)
121 (105–130)
214 (138–258)
129.5 (56–258)
Mean duration ± SD (in days)
71.7 ± 19.9
120.1 ± 7.1
200.9 ± 46.4
153.5 ± 57.1